Product Information |
Product name |
Nifuratel |
CAS No. |
4936-47-4 |
Molecular Formula |
C10H11N3O5S |
Molecular Weight |
285.276 |
Quality Standard |
98.5% up |
Appearance |
Yellow crystalline powder |
COA of Nifuratel |
ITEMS |
SPECIFICATIONS |
RESULTS |
Appearance |
Yellow crystalline powder |
Confirms |
Melting Point |
186.0 。C - 189.0。C |
186.3。C-186.7。C |
PH |
5.8- 7.4 |
7.14 |
Color of solution |
Not deeper than No.5 |
Confirms |
Single impurity |
≤ 0.1% |
0.09%% |
Total impurity |
≤ 1.0% |
0.25% |
Loss on drying |
≤ 0.5% |
0.13% |
Residual on ignition |
≤ 0.1% |
0.03% |
Assay |
98.5%-101.5% |
99.9% |
Conclusion |
Complies with the enterprise standard |
Usage |
Function of Nifuratel
Nifuratel is a gynecological antibacterial drug, mainly used for the treatment of bacterial vaginitis, trichomonal vaginitis, candidal vaginitis and vulvitis, in addition to urinary system infections and digestive amebiasis and Giardiasis and so on.
Nifuratel can be quickly absorbed after oral administration. The peak blood concentration can be reached within 2 hours, and there are reports of high concentration in saliva and vaginal secretions. The half-life is 2.75 hours. Nifuratel is also rapidly metabolized, and most of the oral nifuratel is excreted through the kidneys. Together with the two active metabolites, it is excreted in the urine, and the original drug and metabolites can also be excreted in milk. Nifuratel is effective against bacteria, trichomoniasis and candida that cause infections in women's reproductive system. This product mainly inhibits the growth of bacteria by interfering with its enzyme system. It is difficult to penetrate the placenta and has no teratogenic effect.
*Products under the patent are only for R&D use